This complementary mechanism of action makes the dual inhibition of CTLA‐4 and PD‐1 an appealing approach,9 which has been clinically proved in melanoma10 and renal cell carcinoma.11 The gene discussed is CTLA4; the disease is renal cell carcinoma.